Every September the gold ribbons come out, and every September a statistic gets passed around that most people never actually check. Less than 4% of federal cancer research funding in the United States goes to pediatric cancers. You can argue about the exact number depending on how you count survivorship research or shared-mechanism grants, but the shape of the problem is real. The cancers that kill the most kids get a fraction of what the cancers that kill the most adults get.
The reason is not cruelty. It is mostly math. Federal grants tend to follow disease burden, and burden is usually measured in total deaths or hospitalization days. Pediatric cancers are rare by those metrics. Around 10,500 American children are diagnosed with cancer each year. Breast cancer alone sees about 300,000. When a funding committee compares proposals, the one that touches more people often wins on cost per life year saved.
The pushback on that math is that kids have more life ahead of them, and that a cure at seven is not the same thing as a cure at seventy. Pediatric survivors also live with decades of late effects. Cardiac damage from anthracyclines. Secondary cancers from radiation. Infertility. Neurocognitive issues. These are not edge cases. They are the cost of treatments that were mostly designed for adult biology and scaled down afterwards.
Private foundations exist partly to fill this gap. The National Pediatric Cancer Foundation funds a consortium called the Sunshine Project, where research hospitals run trials on cancers that do not have a viable commercial market. There is no blockbuster drug in a disease that affects a few hundred kids a year. Nobody is going to make that money back on royalties. Someone still has to pay for the science.
That is where student chapters like ours come in. A few thousand dollars a semester will not fund a trial on its own, and it does not need to. NPCF's model is to aggregate thousands of small donors into grants big enough to move a trial forward. Our Chipotle night, on its own, is one night. Added to every other chapter's one night, it becomes real money.
None of this is meant to guilt anyone into donating. It is meant to be honest about why the gap exists in the first place. The funding shortfall is not a fixable bureaucratic glitch. It is a consequence of how cancer research money actually moves in this country. If we want pediatric cancer to get more of it, more people have to keep pushing. That is the whole job.